Misha Rosenbach, MD

Misha Rosenbach, MD, is a professor of dermatology and rheumatology at the Hospital of the University of Pennsylvania

Articles by Misha Rosenbach, MD

Brepocitinib’s Unprecedented Phase 2 Results in Neglected and Rare Cutaneous Disease

ByMisha Rosenbach, MD,Marie Bosslett, Assistant Editor

February 18th 2026

BEACON phase 2 shows brepocitinib delivers dramatic, low-placebo CSAMI improvements with strong safety, Misha Rosenbach, MD reports, boosting hope for cutaneous sarcoidosis.

Misha Rosenbach, MD, on the Clinical and Psychosocial Burden of Cutaneous Sarcoidosis

ByMisha Rosenbach, MD,Marie Bosslett, Assistant Editor

February 17th 2026

Misha Rosenbach, MD, discussed the burden of cutaneous sarcoidosis (CS) and how emerging therapies like brepocitinib could fill this clinical need.

Latest Updated Articles

Brepocitinib’s Unprecedented Phase 2 Results in Neglected and Rare Cutaneous Disease
February 18th 2026
Misha Rosenbach, MD, on the Clinical and Psychosocial Burden of Cutaneous Sarcoidosis
February 17th 2026

Misha Rosenbach, MD

Articles by Misha Rosenbach, MD

Brepocitinib’s Unprecedented Phase 2 Results in Neglected and Rare Cutaneous Disease

Misha Rosenbach, MD, on the Clinical and Psychosocial Burden of Cutaneous Sarcoidosis

Latest Updated Articles

Trending on Dermatology Times

Dermalogica Enters Medical Aesthetics with FDA-Cleared Microneedling PRO Pen

Social Media Mythbusters: Hypochlorous Acid Sprays

Quoin Submits First-Ever IND Application for Peeling Skin Syndrome Therapy

Topical GX-03 Hits 92.6% EASI-50 at Week 4 in Phase 2 AD Interim

SkinJect Advances into Registrable Development as Potential First-in-Class Therapy for Gorlin Syndrome